Response of leprosy patients with single lesions to MDT.
Acta Leprol
; 9(3): 133-7, 1995.
Article
em En
| MEDLINE
| ID: mdl-7631584
This study reports the clinical profile and therapeutic response of seventy-two mono-lesions leprosy cases. These 72 cases were among 578 paucibacillary (PB) cases classified according to WHO (1982) and were followed-up on multidrug therapy (MDT). Of these 72 mono-lesion cases, 46 (64%) were tuberculoid (TT) cases, 24 (33%) were Indeterminate (Ind) cases and 2 (3%) were of borderline tuberculoid (BT) types. While 37.5% of these cases presented as macular patches, the remaining 62.5% had raised erythematous lesions. In majority of cases (94%), the lesions were present on the exposed parts like legs and feet, arms and hands, face, whereas only 6% presented on covered areas of trunk and buttocks. These cases were treated with dapsone 100 mg daily for 12 months and rifampicin 600 mg once a month for 6 months. After 6 months of MDT, lesions in 81% of the patients regressed clinically and by one year of therapy 96% of cases had regressed. Treatment was stopped in all cases by one year of therapy. There were no relapse or late reaction in the 5 years of post treatment follow-up. The response of mono-lesion PB cases was better than the multi-lesions PB cases at 6 months and during the post treatment follow-up period.
Buscar no Google
Tema:
Complicacoes
/
Epidemiologia
/
Geral
/
Prevencao_controle
/
Tratamento_medicamentoso
Bases de dados:
MEDLINE
Assunto principal:
Rifampina
/
Hanseníase Tuberculoide
/
Dapsona
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Acta Leprol
Ano de publicação:
1995
Tipo de documento:
Article